



Randomized multi-centric trial

300 involved patients

270 days of monitoring for each patients

6 pilot centers in UK, SPAIN, SWEDEN, SLOVENIA, ESTONIA



















Dr. Eng. Roberto Rosso TESAN S.p.A via L.L. Zamenhof 200 36100 Vicenza - Italy Email: rosso@tesan.it Tel: +39 0444 914701


www.chromed.eu

CHROMED project is partially funded by European Commission under FP7





Clinical trials for elderly patients with multiple disease





The project

CHROMED is an innovative European project aimed at improving the health status and lifestyle of elderly people, suffering of Chronic Obstructive Pulmonary Disease (COPD) and cardiac comorbidities, as Chronic Heart Failure (CHF).

A clinical trial involving 300 patients and 7 clinical centre in all Europe has been carried on to evaluate clinical protocols and organizational models based on new technologies, to evaluate the impact of a new integrated home care approach to reduce care costs and improve quality of life in COPD patients.

Background

COPD is a significant socio-economic burden. Worldwide, COPD affects 329 million people, nearly 5% of the population. In 2011, it ranked as the fourth-leading cause of death, killing over 3 million people. The number of deaths is projected to increase because of an ageing population in many countries. It resulted in an estimated economic cost of \$2.1 trillion in 2010. Telemedicine-based care models that enable early diagnosis and treatment of exacerbations are advocated to reduce the socioeconomic impact of chronic diseases.

The Chromed system

The monitoring system includes a forced oscillation technique (FOT) device for self-measurement of lung mechanics (Resmon Pro Diary, Restech srl, Italy), a touch screen for collecting patient's symptoms and, for subjects with CHF comorbidity, a device for measuring heart rate (HR), blood pressure (BP), (SpO2) and body temperature (WRIST CLINIC, Medic4all, Israel).

Target

CHROMED is an ambitious project involving different users at different levels:

Elderly patients will receive personalized care assistance, ease communication with doctors, continuous monitoring of their health status. That is, improvement in their quality of life.

Clinicians able to assist elderly people from home, reducing hospitalization and exacerbation.

Enterprises, will get large scale validation, know-how development, improvement of the devices according to the users experience and international standards.

Public health authorities, who will find new tools for the prevention of COPD exacerbation with a consequent reduction of costs for hospital readmission and visits, and improvements of the effectiveness of therapies.

